Cannara Biotech Inc. (CSE:LOVE) has launched its campaign on the Investing News Network’s Cannabis and Life Science channels.

Cannara Biotech is building a vertically-integrated cannabis company focused on cultivating and developing cannabis-infused products at their 625,000-square-foot indoor cultivation facility – one of the largest in Canada and largest to date in Quebec. Once operational, the facility will contain 500,000 square feet of production space, 100,000 square feet of processing space and will have an annual production capacity of 100,000 kilograms of cannabis.


Through Cannara’s collaborative corridor initiative, the company intends to lease space to product manufacturers developing cannabis-infused products and expedite them to the market. Cannara is currently in discussions with partners to produce edibles, pet products, cosmetics, beverages and more within the facility, once the appropriate regulations come into effect.

In addition to their facility in Quebec, Cannara has entered the US hemp and cannabidiol (CBD) market through the e-commerce platform, shopCBD.com, which will showcase hemp and CBD manufacturers throughout the US. The site will offer tinctures, oils, capsules, body care, vape cartridges and pet-related products to US consumers.

Cannara’s company highlights include the following:

  • Canadian cannabis sales expected to reach $7.17 billion in 2019.
  • Quebec’s recreational cannabis market expected to generate between $420 million and $1 billion in sales in 2019.
  • Quebec has lowest cost per gram and electricity rates in Canada.
  • 625,000-square-foot indoor, multi-purpose cultivation facility under construction in Farnham, Quebec.
  • Phase one construction fully-funded. Phases two and three to be funded through tenants.
  • IP portfolio with 19 filed patents and 40 granted domain names and trademarks.
  • Seven brands across medical, recreational, pet care, cosmeceutical, beverage and edible markets.
  • Ongoing R&D to develop new products and formulations to address consumer demand.
  • US hemp-derived CBD market is expected to reach $22 billion by 2022.

Click here to see the educational profile for Cannara Biotech Inc. (CSE:LOVE) and to request an investor presentation.

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less